2026 ICD-10-CM Diagnosis Code C25.3Malignant neoplasm of pancreatic duct

ICD-10-CM Codes›C00–D49›C15-C26›C25

ICD-10-CM C25.3
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C25.3 is a billable ICD-10-CM diagnosis code for malignant neoplasm of pancreatic duct. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 435 through 437. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Endocrine system cancers - pancreas.

Code Identity

ICD-10-CM Code
C25.3
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of pancreatic duct
Short Description
Malignant neoplasm of pancreatic duct
Same as the full description in the CMS dataset.
Parent Code
C25
Malignant neoplasm of pancreas

Code Classification

ChapterC00–D49Neoplasms
SectionC15-C26Malignant neoplasms of digestive organs
CategoryC25Malignant neoplasm of pancreas
This CodeC25.3Malignant neoplasm of pancreatic duct

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Infiltrating duct carcinoma of pancreas
  • Intraductal papillary mucinous neoplasm of pancreas
  • Intraductal tubulopapillary malignant neoplasm of pancreas
  • Invasive intraductal papillary-mucinous carcinoma of pancreas
  • Malignant neoplasm of pancreatic duct
  • Pancreatic ductal adenocarcinoma
  • Primary adenocarcinoma of pancreas
  • Primary adenocarcinoma of pancreatic duct
  • Primary infiltrating duct carcinoma of pancreas
  • Primary invasive intraductal papillary-mucinous carcinoma of pancreas
  • Primary malignant neoplasm of pancreatic duct
  • Primary mixed acinar ductal carcinoma of pancreas
  • Undifferentiated carcinoma with osteoclast-like giant cells of pancreas

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO051
Endocrine system cancers - pancreas
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary		Malig.
Secondary		Ca
in situ		BenignUncertainUnspec.
pancreas › duct (of Santorini) (of Wirsung)C25.3C78.89D01.7D13.6D37.8D49.0
Santorini's ductC25.3C78.89D01.7D13.6D37.8D49.0
Wirsung's ductC25.3C78.89D01.7D13.6D37.8D49.0

Patient EducationClinical

Pancreatic Cancer

The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C25.3 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
157.3 Mal neo pancreatic duct
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C25.3Overview

Is C25.3 (Malignant neoplasm of pancreas) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of pancreatic duct on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C25.3 group to?

When malignant neoplasm of pancreatic duct is the principal diagnosis on an inpatient stay, it groups to MS-DRG 435, 436, 437, with relative weights from 0.8533 to 1.8367 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C25.3?

Under the General Equivalence Mappings, malignant neoplasm of pancreatic duct converts to ICD-9-CM 157.3 (mal neo pancreatic duct). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.